Proteomics

Dataset Information

0

Proteomics analysis in DIA mode of 24 weeks from the sorafenib treated and vehicle treated monkeys


ABSTRACT: Quantitative proteomics in DIA mode was used to analysis the proteomic profile of 24 weeks from the sorafenib treated and vehicle treated monkeys.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Macaca Fascicularis Fascicularis

TISSUE(S): Liver

DISEASE(S): Non-alcoholic Steatohepatitis

SUBMITTER: Xu Cheng  

LAB HEAD: Hongliang Li

PROVIDER: PXD018256 | Pride | 2022-08-30

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Macacafascicularis_peptiede_Report.xls Xls
Macacafascicularis_protein_Report.xls Xls
P201901748_101-12-7_Veh.raw Raw
P201901748_101-15-7_Veh.raw Raw
P201901748_101-18-7_Veh.raw Raw
Items per page:
1 - 5 of 8
altmetric image

Publications


Nonalcoholic steatohepatitis (NASH) is becoming one of the leading causes of hepatocellular carcinoma (HCC). Sorafenib is the only first-line therapy for advanced HCC despite its serious adverse effects. Here, we report that at an equivalent of approximately one-tenth the clinical dose for HCC, sorafenib treatment effectively prevents the progression of NASH in both mice and monkeys without any observed significant adverse events. Mechanistically, sorafenib's benefit in NASH is independent of it  ...[more]

Similar Datasets

2021-02-25 | PXD022952 | Pride
2021-02-25 | PXD022627 | Pride
2018-11-28 | PXD011537 | Pride
2020-11-04 | PXD016358 | Pride
2019-11-08 | PXD012987 | Pride
2023-10-24 | PXD040173 | Pride
2019-11-08 | PXD012988 | Pride
2021-04-20 | PXD017199 | Pride
2019-03-20 | PXD010912 | Pride
2020-01-06 | PXD011382 | Pride